Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Filing Letter - Cervarix, April 9, 2007

April 9, 2007

GlaxoSmithKline Biologicals
Attention: Ms. Sharon W. Shapowal
230 I Renaissance Boulevard
P.O. Box 61540
King of Prussia, PA 19406-2772

Dear Ms. Shapowal:

We have received your biologics license application (BLA) submitted under section 351 of the Public Health Service Act for the following biological product:
Our Submission Tracking Number (STN): BL 125259/0
Biological Product: Human Papillomavirus Vaccine, AS04 Adjuvant-Adsorbed
Indication: Active immunization to prevent cervical cancer in females 10 years of age and older.
Date of Supplement: March 29,2007
Date of Receipt: March 29, 2007
First Action Due Date: January 28, 2008
US License: 1617

Please submit all future correspondence, supporting data, or labeling relating to this application in triplicate, citing the above STN number. Send all correspondence to the following address:

We will notify you within 60 days of the receipt date if the application is sufficiently
complete to permit a substantive review.

Norman Baylor, Ph.D., HFM-475
Center for Biologics Evaluation and Research
Food and Drug Administration
Suite 200N
1401 Rockville Pike
Rockville, MD 20852-1448

 

We wil notify you within 60 days of the receipt date if the application is sufficiently complete to permit a substantive review.

If you have any questions, please contact Ms. Helen Gemignani, Regulatory Project Manager, at (301) 827-3070.
Sincerely yours,
Loris D. McVittie, Ph.D.
Chief
Viral Vaccine Branch
Division of Vaccines and
Related Products Applications
Offce of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 04/09/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.